The European Commission has approved Enspryng for treatment of adults and adolescents with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum disorder, according to a Roche press release.
Enspryng (satralizumab), a subcutaneous injection administered every 4 weeks, may be used as monotherapy or in combination with immunosuppressive therapy in people aged 12 years and older, with home-dosing being an option after appropriate training, the release said.
“Building on our growing scientific understanding of neuroimmunological conditions, we are confident Enspryng can transform